Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

What this study is about

Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.

Who can join (things the study team will check)

✅ You may be able to join if…

• Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active treatment in a belzutifan parent study.

🚫 You may not be able to join if…

• Has an on-going serious adverse event in the parent study, unless no longer hospitalized and considered clinically stable.
• Is currently on a dose interruption due to an Adverse Event (AE) in the parent study; once treatment has been resumed in the parent study, the participant is eligible to enroll.

Where this trial is running

• Beth Israel Deaconess Medical Center ( Site 0107), Boston, Massachusetts, United States
• Dana-Farber Cancer Institute ( Site 0105), Boston, Massachusetts, United States
• Karmanos Cancer Center ( Site 0108), Detroit, Michigan, United States
• START San Antonio ( Site 0104), San Antonio, Texas, United States
• UZ Leuven ( Site 0900), Leuven, Vlaams-Brabant, Belgium
• Département clinique de médecine de laboratoire du CHUM ( Site 0001), Montreal, Quebec, Canada
• Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 1000), Olomouc, Czechia
• Tampereen yliopistollinen sairaala ( Site 1305), Tampere, Pirkanmaa, Finland
• Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 1501), Budapest, Hungary
• Rambam Health Care Campus ( Site 1600), Haifa, Israel
• Hadassah Medical Center ( Site 1604), Jerusalem, Israel
• Rabin Medical Center ( Site 1602), Petah Tikva, Israel

+ 15 more sites.

Who to contact

Toll Free Number · 1-888-577-8839 · Trialsites@msd.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07405164.